M
Meike Witt
Publications - 3
Citations - 1613
Meike Witt is an academic researcher. The author has contributed to research in topics: Cancer & Immunotherapy. The author has an hindex of 3, co-authored 3 publications receiving 1173 citations.
Papers
More filters
Journal ArticleDOI
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Ugur Sahin,Evelyna Derhovanessian,Matthias Miller,Björn-Philipp Kloke,Petra Simon,Martin Löwer,Valesca Bukur,Arbel D. Tadmor,Ulrich Luxemburger,Barbara Schrörs,Tana Omokoko,Mathias Vormehr,Christian Albrecht,Anna Paruzynski,Andreas Kuhn,Janina Buck,Sandra Heesch,Katharina H Schreeb,Felicitas Müller,Inga Ortseifer,Isabel Vogler,Eva Godehardt,Sebastian Attig,Richard Rae,Andrea Breitkreuz,Claudia Tolliver,Martin Suchan,Goran Martic,Alexander Hohberger,Patrick Sorn,Jan Diekmann,Janko Ciesla,Olga Waksmann,Alexandra-Kemmer Brück,Meike Witt,Martina Zillgen,Andrée Rothermel,Barbara Kasemann,David Langer,Stefanie Bolte,Mustafa Diken,Sebastian Kreiter,Romina Nemecek,Christoffer Gebhardt,Christoffer Gebhardt,Stephan Grabbe,Christoph Höller,Jochen Utikal,Jochen Utikal,Christoph Huber,Carmen Loquai,Özlem Türeci +51 more
TL;DR: The first-in-human application of individualized mutanome vaccines in melanoma is reported, demonstrating that individual mutations can be exploited and opening a path to personalized immunotherapy for patients with cancer.
Proceedings ArticleDOI
Abstract CT032: A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles for potent cancer immunotherapy in patients with malignant melanoma
Robert A. Jabulowsky,Carmen Loquai,Mustafa Diken,Lena M. Kranz,Heinrich Haas,Sebastian Attig,Nicole Bidmon,Janina Buck,Evelyna Derhovanessian,Jan Diekmann,Daniel Fritz,Veronika Jahndel,Alexandra Kemmer-Brueck,Klaus Kuehlcke,Andreas Kuhn,Peter Langguth,Ulrich Luxemburger,Martin Meng,Felicitas Mueller,Richard Rae,Fatih Sari,Doreen Schwarck-Kokarakis,Christine Seck,Kristina Spieß,Meike Witt,Jessica C. Hassel,Jochen Utikal,Roland Kaufmann,Sebastian Kreiter,Christoph Huber,Oezlem Tuereci,Ugur Sahin +31 more
TL;DR: A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles for potent cancer immunotherapy in patients with malignant melanoma and potential clinical activity of the RNA(LIP) immunotherapy concept is evaluated.
Proceedings ArticleDOI
Abstract B041: A novel nanoparticular formulated tetravalent RNA cancer vaccine for treatment of patients with malignant melanoma
Robert A. Jabulowsky,Carmen Loquai,Mustafa Diken,Lena M. Kranz,Heinrich Haas,Sebastian Attig,Cedrik M. Britten,Janina Buck,Evelyna Derhovanessian,Jan Diekmann,Isaac Esparza,Daniel Fritz,Yves Huesemann,Veronika Jahndel,Klaus Kuehlcke,Andreas Kuhn,Peter Langguth,Ulrich Luxemburger,Martin Meng,Felicitas Mueller,Kerstin C. Reuter,Doreen Schwarck,Kristina Spiess,Meike Witt,Jessica C. Hassel,Jochen Utikal,Roland Kaufmann,Marc Schrott,Sebastian Kreiter,Oezlem Tuereci,Christoph Huber,Ugur Sahin +31 more
TL;DR: The clinical translation of this pioneering therapeutic concept is currently being realized in a multi-center, first-in-human phase I trial in patients with malignant melanoma to study safety, tolerability, and immunogenicity of this innovative immunotherapy approach.